The FDA granted orphan drug status to rhenium-186 obisbemeda for treating leptomeningeal metastases in lung cancer.

Ian Everard warns of a looming precious metals supply crunch. He highlights manipulated markets, dwindling silver stocks, and ...

Plus Therapeutics (PSTV) announces that the U.S. Food and Drug Administration has granted Orphan Drug Designation to Rhenium Obisbemeda for the ...

A drug developed at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has been shown to ...

The American Cancer Society awarded its 2025 Medal of Honor to W. Kimryn Rathmell, MD, PhD, renowned kidney cancer expert and ...

Plus Therapeutics (PSTV) announced the completion of the ReSPECT-LM Phase 1 single-dose escalation trial, having determined an RP2D. The ...

ReSPECT- LM Phase 1 single dose is now complete, and the recommended Phase 2 dose (RP2D) for single administration therapy has been determinedAUSTIN, Texas, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Plus ...

Plus Therapeutics stock rises after peer-reviewed publication of Phase 1 glioma data and FDA Orphan Drug Designation for lung ...

The FDA bestows an Orphan Drug tag to Plus Therapeutics' investigational drug, rhenium (186Re) obisbemeda, for treating leptomeningeal metastases in lung cancer patients.

Researchers have developed a drug shown to significantly extend survival time for patients with glioblastoma, the most common primary brain tumor in adults, according to results of a new trial.

An investigational drug for glioblastoma more than doubled survival and progression-free time compared to standard rates. | ...

Plus Therapeutics, Inc. (Nasdaq: PSTV ) (the “Company” or “Plus Therapeutics”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for ...